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In this issue of Blood, Jitschin et al provide compelling evidence that increased mitochondrial oxidative phosphorylation and production of reactive oxygen species (ROS) leads to reduced T-cell immune function. 1 A half-century ago, Warburg postulated that mitochondrial respiration is impaired in cancer cells and the failure of adenosine triphosphate (ATP) production by mitochondria is compensated by an increased anaerobic glycolysis. 2 antioxidant N-acetyl-cysteine (NAC) prevented CLL cell-mediated T-cell dysfunction. Intracellular ROS are often generated via the catalytic action of NADHP oxidase (NOX) and/or the mitochondrial electron transport chain (mETC) which is cell type-dependent. The authors found that CLL cells have lower expression of gp91, a subunit of NOX, compared with normal B cells. CLL and normal B cells showed a similar capacity in responding to stimulation of NOX by either an increase in its substrate or induction of respiratory burst by phorbol 12-myristate 13-acetate, indicating that NOX is not responsible for ROS overproduction by CLL cells. Gene expression of intracellular antioxidants catalase and heme oxygenase-1 (HO-1) was significantly increased in CLL cells. By contrast, mitochondrial manganese superoxide dismutase (MnSOD) expression was significantly reduced in CLL cells. Jitschin and colleagues suggested that significantly increased mitochondrial superoxide production might be caused, at least in part, by reduced levels of MnSOD. To further identify the ROS generation system in CLL cells, the mitochondrial targeting antioxidant MitoQ and NOX inhibitor diphenyleneiodonium were used to inhibit ROS production. Only MitoQ led to a significant reduction of ROS production, indicating that mitochondria are the source of ROS production in CLL cells.
Using multiple techniques, the authors thoroughly demonstrate that CLL cells have an increased mitochondrial biogenesis, such as increased mitochondrial mass, membrane potential, ATP production, mitochondrial DNA copy numbers, oxygen consumption, and mETC activity. Mitochondrial transcription factor (TFAM) is highly expressed in CLL cells and this may lead to an increased mitochondrial mass. However, aerobic glycolysis is not increased in CLL cells compared with normal B cells. This supports our previous finding that leukemic cells meet high energy demand by increasing mETC activity, rather than increasing aerobic glycolysis. 6 The superoxide radical is generated by mitochondrial complex I and III as an incompletely reduced by-product. ROS production is often induced when mETC is uncoupled with ATP synthesis. 7 Interestingly, this study found that the mitochondria in CLL cells are in a perfectly coupled condition. To connect ROS production and mitochondrial biogenesis, Jitschin et al manipulated redox status by treating CLL cells with antioxidants NAC or MitoQ and found that expression of both TFAM and HO-1 was reduced after treatment with an antioxidant. Interestingly, inhibition of HO-1 by SnPP significantly reduced TFAM expression. Therefore, the authors drew an indirect interconnection between ROS production, cellular adaption to ROS, and mitochondrial biogenesis. Finally, PK11195, a benzodiazepine derivate inhibitor for F1F0-ATPase, the complex V of mETC, was used to block oxidative phosphorylation. PK11195-mediated overproduction of superoxide selectively induced apoptosis in CLL B cells, leaving T cells and normal B cells unaffected.
Therefore, the authors propose 2 opposite therapeutic redox-manipulating strategies for CLL (see figure) . First, treatment of CLL cells using antioxidants could neutralize endogenous ROS and protect the immune system. Second, induction of ROS overproduction by targeting mETC could selectively kill CLL cells. Thus, mitochondria, the source of dangerous power in CLL, need to be controlled in favor of the immune system and can be used as a killer within the CLL cells. This study improves our understanding that leukemic cells circulating in a normoxic condition rely on mitochondrial oxidative phosphorylation for energy supply. This is distinct from solid tumor cells which grow in the hypoxia condition with dysfunctional mitochondria and therefore mainly rely on anaerobic glycolysis. Tumor cells produce higher levels of ROS by dysfunctional mitochondria. The causes of ROS overproduction by CLL mitochondria pose challenging questions. It is not yet clear how increased ROS levels are generated by functional coupled mETC and whether this is merely due to increased mitochondrial biogenesis in CLL cells.
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